237 related articles for article (PubMed ID: 25868485)
41. Different predictive values of interim
Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
[TBL] [Abstract][Full Text] [Related]
42. 18F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: a systematic review and meta-analysis.
Wu LM; Chen FY; Jiang XX; Gu HY; Yin Y; Xu JR
Eur J Radiol; 2012 Feb; 81(2):303-11. PubMed ID: 21145680
[TBL] [Abstract][Full Text] [Related]
43. Diagnostic Performance of Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography With or Without Computed Tomography in Patients With Primary Central Nervous System Lymphoma: Updated Systematic Review and Diagnostic Test Accuracy Meta-analyses.
Gupta T; Manjali JJ; Kannan S; Purandare N; Rangarajan V
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):497-507. PubMed ID: 33947632
[TBL] [Abstract][Full Text] [Related]
44. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
[TBL] [Abstract][Full Text] [Related]
45. Bone marrow FDG-PET/CT in Hodgkin lymphoma revisited: do imaging and pathology match?
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Ann Nucl Med; 2015 Feb; 29(2):132-7. PubMed ID: 25348549
[TBL] [Abstract][Full Text] [Related]
46. The Role of (18)F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis.
Liu Q; Wang C; Li P; Liu J; Huang G; Song S
Biomed Res Int; 2016; 2016():3746232. PubMed ID: 26981529
[TBL] [Abstract][Full Text] [Related]
47. Improvements in Imaging of Hodgkin Lymphoma: Positron Emission Tomography.
Hutchings M
Cancer J; 2018; 24(5):215-222. PubMed ID: 30247256
[TBL] [Abstract][Full Text] [Related]
48. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis.
Zou Y; Tong J; Leng H; Jiang J; Pan M; Chen Z
Oncotarget; 2017 Jun; 8(25):41518-41528. PubMed ID: 28514747
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
Zhao J; Qiao W; Wang C; Wang T; Xing Y
Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
[TBL] [Abstract][Full Text] [Related]
50. Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?
Gallamini A; Kostakoglu L
Blood; 2012 Dec; 120(25):4913-20. PubMed ID: 22932799
[TBL] [Abstract][Full Text] [Related]
51. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
52. End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis.
Pyo J; Won Kim K; Jacene HA; Sakellis CG; Brown JR; Van den Abbeele AD
Clin Cancer Res; 2013 Dec; 19(23):6566-77. PubMed ID: 24052020
[TBL] [Abstract][Full Text] [Related]
53. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
Evens AM; Kostakoglu L
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):135-43. PubMed ID: 25696846
[TBL] [Abstract][Full Text] [Related]
54. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis.
Terasawa T; Dahabreh IJ; Nihashi T
Oncologist; 2010; 15(7):750-9. PubMed ID: 20587551
[TBL] [Abstract][Full Text] [Related]
55. The role of fluorine-18 fluorodeoxyglucose PET in prognosis evaluation for stem cell transplantation of lymphoma: a systematic review and meta-analysis.
Wang C; Li P; Wu S; Lu J; Liu Q; Luo H; Song S
Nucl Med Commun; 2016 Apr; 37(4):338-47. PubMed ID: 26741290
[TBL] [Abstract][Full Text] [Related]
56. Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes.
Terasawa T; Nagai H
Leuk Lymphoma; 2009 Nov; 50(11):1750-2. PubMed ID: 19863179
[TBL] [Abstract][Full Text] [Related]
57. Diagnostic performance of dual-time 18F-FDG PET in the diagnosis of pulmonary nodules: a meta-analysis.
Barger RL; Nandalur KR
Acad Radiol; 2012 Feb; 19(2):153-8. PubMed ID: 22104289
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598
[TBL] [Abstract][Full Text] [Related]
59. Prognostic significance of (18)F-FDG PET at diagnosis in patients with soft tissue sarcoma and bone sarcoma; systematic review and meta-analysis.
Kubo T; Furuta T; Johan MP; Ochi M
Eur J Cancer; 2016 May; 58():104-11. PubMed ID: 26990930
[TBL] [Abstract][Full Text] [Related]
60. 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: a meta-analysis.
Hongtao L; Hui Z; Bingshun W; Xiaojin W; Zhiyu W; Shuier Z; Aina H; Yuanjue S; Daliu M; Zan S; Yang Y
Surg Oncol; 2012 Dec; 21(4):e165-70. PubMed ID: 22884956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
